LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Search

Charles River Laboratories International Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

168.66 -1.6

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

167.72

Max

174.52

Pagrindiniai rodikliai

By Trading Economics

Pajamos

2.9M

56M

Pardavimai

-27M

1B

P/E

Sektoriaus vid.

592.3

105.69

Pelnas, tenkantis vienai akcijai

2.43

Pelno marža

5.529

Darbuotojai

18,700

EBITDA

-23M

198M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+11.95% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-487M

8.3B

Ankstesnė atidarymo kaina

170.26

Ankstesnė uždarymo kaina

168.66

Naujienos nuotaikos

By Acuity

21%

79%

49 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Charles River Laboratories International Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-13 21:34; UTC

Uždarbis

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

2025-11-13 23:45; UTC

Rinkos pokalbiai

Nikkei May Fall After Wall Street's Weakness -- Market Talk

2025-11-13 23:42; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

2025-11-13 23:41; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Dip-Buying -- Market Talk

2025-11-13 23:24; UTC

Uždarbis

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

2025-11-13 23:24; UTC

Uždarbis

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

2025-11-13 23:23; UTC

Uždarbis

JBS NV 3Q EPS 52c >JBS

2025-11-13 23:23; UTC

Uždarbis

JBS NV 3Q Sales $22.6B >JBS

2025-11-13 23:04; UTC

Rinkos pokalbiai

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

2025-11-13 22:02; UTC

Uždarbis

Nu Holdings 3Q Net $783M >NU

2025-11-13 22:01; UTC

Uždarbis

Nu Holdings 3Q Rev $4.2B >NU

2025-11-13 21:51; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

2025-11-13 21:50; UTC

Uždarbis

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

2025-11-13 21:45; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

2025-11-13 21:41; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

2025-11-13 21:33; UTC

Rinkos pokalbiai

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

2025-11-13 21:33; UTC

Uždarbis

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

2025-11-13 21:31; UTC

Uždarbis

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

2025-11-13 21:25; UTC

Uždarbis

Figure Tech Solutions 3Q Rev $156.4M >FIGR

2025-11-13 21:25; UTC

Uždarbis

Figure Tech Solutions 3Q EPS 34c >FIGR

2025-11-13 21:23; UTC

Uždarbis

Intchains Group 3Q Rev $1.3M >ICG

2025-11-13 21:03; UTC

Uždarbis

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

2025-11-13 21:02; UTC

Uždarbis

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

2025-11-13 21:01; UTC

Uždarbis

Applied Materials 4Q Rev $6.8B >AMAT

2025-11-13 21:01; UTC

Uždarbis

Applied Materials 4Q Gross Margin 48.0% >AMAT

Akcijų palyginimas

Kainos pokytis

Charles River Laboratories International Inc Prognozė

Kainos tikslas

By TipRanks

11.95% į viršų

12 mėnesių prognozė

Vidutinis 192 USD  11.95%

Aukščiausias 225 USD

Žemiausias 165 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Charles River Laboratories International Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

12 ratings

6

Pirkti

6

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

117.16 / 144.77Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

49 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat